On Sept. 4, the U.S. Food and Drug Administration (FDA) approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria, a rare metabolic disorder that has been reported in about 20 patients worldwide.

FDA approves drug for rare metabolic disorder

Risk for second surgery to remove vaginal mesh low

Mindfulness mediation may affect memory

Quiz time – 9/8

FDA approves new drugs

ANA releases new position statement on workplace bullying

Drinking water before eating facilitates weight loss

Racial bias in health care

FDA approves drug for sexual desires disorders in women

ISMP releases IV push meds guidelines

Detecting more abdominal aortic aneurysms

Quiz time – 8/18/15

Risk/benefit ratio for statins

Troponin may help predict cardiac events

Meniscal transplants can relive pain, delay surgery

Computer algorithm can predict septic shock

Why is nursing’s voice absent from population health management strategy?

Boost your confidence in caring for patients with insulin pumps

Proactive intervention for osteoarthritis

What you say to yourself

From our readers: When your parent is the patient

Enhance your self-awareness to be an authentic leader

What works: Measuring acuity on a medical-surgical unit

A bold call to action: Mobilizing nurses and employers to prevent and address incivility, bullying, and workplace violence

Recommendations to make cancer drugs more affordable

Sexual assault screening in the outpatient setting

Neurocysticercosis: More than a headache

Exploring childcare health consultant as a career option

Quiz Time – 8/4/15

Teenage binge eating may be result of gene variation

FDA approves new cholesterol-lowing drug

FDA approves new device for treating obesity

ACA improves care

FDA authorizes prosthesis for above-the-knee amputations

Lower ankle brachial index associated with mild cognitive impairment

Our Readers Respond